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ABSTRACT

Objective: To determine whether insurance status is associated with differential outpatient treatment of migraine in the United States.

Methods: We analyzed 11 years of data from the National Ambulatory Medical Care Survey and
National Hospital Ambulatory Medical Care Survey (1997–2007), which survey patient visits to
doctors’ offices, hospital outpatient departments, and emergency departments (EDs) in the
United States. We used logistic regression to determine whether insurance status was associated with the prescription of standard migraine therapy, defined as 1) a triptan or dihydroergotamine and 2) a prophylactic agent.
Results: We identified 6,814 individual patient visits for migraine, representing 68.6 million visits
nationally. After controlling for age, gender, race/ethnicity, geographic location, and year, migraineurs with no insurance or Medicaid were less likely than the privately insured to receive
abortive therapy (odds ratio [OR] for failure to receive medication 2.0 [95% confidence interval
(CI) 1.3, 3.0] and 1.6 [95% CI 1.1, 2.3]) and prophylactic therapy (OR 2.0 [95% CI 1.3, 2.9] and
1.5 [95% CI 1.0, 2.1]). Adding site of care to the regression model suggested that one mechanism for this discrepancy was the reliance of the uninsured on EDs for migraine care, a site where
standard migraine care is often omitted (OR for failure to receive abortive and prophylactic medication in the ED relative to physicians’ offices 4.8 [95% CI 3.6, 6.3] and 8.7 [95% CI 6.4, 11.7]).
Conclusions: The uninsured, and those with Medicaid, receive substandard therapy for migraine,
at least in part because they receive more care in emergency departments and less in physicians’
offices. Neurology® 2010;74:1178 –1183
GLOSSARY
AAN ⫽ American Academy of Neurology; CI ⫽ confidence interval; DHE ⫽ dihydroergotamine; ED ⫽ emergency department;
ICD-9-CM ⫽ International Classification of Diseases, Ninth Revision, Clinical Modification; NAMCS ⫽ National Ambulatory
Medical Care Survey; NCHS ⫽ National Center for Health Statistics; NHAMCS ⫽ National Hospital Ambulatory Medical Care
Survey; NSAID ⫽ nonsteroidal anti-inflammatory drug; OPD ⫽ outpatient department; OR ⫽ odds ratio.

Migraine headache is common, affecting 18% of American women and 6% of men.1,2 The
condition disables over half its sufferers, reducing both quality of life and productivity.2 A large
survey of migraineurs found that 91% reported functional impairment from migraines; thus,
most migraine is moderate to severe.2 Migraineurs lose 4 to 6 work days each year due to
headache and cost American employers as much as $17 billion annually.3,4 Optimal migraine
treatment is important for both patients and society.
The evidence-based practice parameter of the American Academy of Neurology (AAN)
recommends a triptan or dihydroergotamine (DHE) as first-line therapy for moderate or severe
migraine, based on their superiority to nonsteroidal anti-inflammatory drugs (NSAIDs), and
older migraine-specific medications such as ergotamine/caffeine.5-9 Migraineurs prefer treatment that includes a triptan over an analgesic alone.10,11 The AAN recommends prophylactic
therapy for patients whose migraines are frequent, severe, incompletely responsive to abortive

From the Department of Veterans Affairs (A.W.), Boise VA Medical Center, University of Washington School of Medicine, Seattle; and Cambridge
Hospital (S.W., D.H., R.N.), Harvard Medical School, Cambridge, MA.
Disclosure: Author disclosures are provided at the end of the article.
1178

Copyright © 2010 by AAN Enterprises, Inc.

therapy, or disabling.5 Prophylaxis has been
shown to reduce the use of abortive medications, as well as physician and ED visits, making it a cost-effective element of migraine
care.12
Standard migraine therapy for most migraine, which is moderate to severe, thus consists of a triptan or DHE as abortive therapy
plus a prophylactic medication for those patients with frequent or incompletely responsive migraines. We hypothesize that one of
the factors influencing whether a patient receives standard migraine therapy in the ambulatory setting is health insurance. In this
study, we examine a nationally representative
sample of adult visits for migraine to ambulatory settings in the United States to assess the
effect of insurance status on the receipt of
standard migraine therapy.
METHODS Data source. We analyzed the National Hospital Ambulatory Medical Care Survey (NHAMCS) and the National Ambulatory Medical Care Survey (NAMCS). The
National Center for Health Statistics (NCHS) conducts both
NHAMCS and NAMCS; NHAMCS assesses ambulatory visits
to hospital outpatient departments (OPD) and EDs, whereas
NAMCS assesses ambulatory visits to office-based physicians.
Both surveys use virtually identical questions and are designed to
be nationally representative; jointly, they provide a comprehensive view of ambulatory care visits in the United States.
The surveys’ methodologies have been described elsewhere.13
In brief, the NHAMCS uses a 4-stage probability design to select
geographic regions, hospitals within each region, clinics and
emergency service areas within the hospitals, and patient visits
within the service areas. Federal hospitals are excluded. Field
representatives of the US Census Bureau train hospital staff to
complete survey forms for visits during a randomly assigned,
4-week reporting period. Information is recorded on age, race/
ethnicity, gender, expected sources of payment, 1 primary and 2
other diagnoses, medical professionals seen during the visit, and
medications given or prescribed during the visit. NHAMCS also
records hospital characteristics including ownership (government; voluntary, nonprofit; or proprietary), region, and urban
(metropolitan statistical area) vs nonurban (non-metropolitan
statistical area) location. Unless it is hospital policy to ask patients for race/ethnicity, hospital personnel record race/ethnicity
based on observations. Race is categorized as white, black/
African American, Asian, Native Hawaiian/other Pacific Islander, American Indian, or Alaska Native. Hispanic ethnicity is
coded separately. NHAMCS categorizes anticipated source of
payment as private insurance, Medicare, Medicaid, worker’s
compensation, self-pay, or no charge, as well as other, unknown,
or blank (which we combined into a single category). NHAMCS
codes diagnoses based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).
NAMCS is a survey of visits to physicians who are officebased, principally engaged in patient care, non-federally employed, and not practicing anesthesiology, pathology, or
radiology. NAMCS employs a 3-stage design that selects geo-

graphic regions, physician practices in each region, and patient
visits within each practice. During a randomly assigned,
1-week reporting period, each selected physician or office
staff records data from patient visits. NAMCS collects patient
data similar to that collected in NHAMCS, but also includes
physician specialty.

Study population. We analyzed 11 years of NAMCS and
NHAMCS data, from 1997–2007. Injectable sumatriptan became available in the United States in 1991 and oral sumatriptan
in 1995; we began our data analysis a couple of years after this to
ensure that knowledge and use of triptans would be widespread.
We included all adult patient visits coded for either common or
classic migraine, with or without intractability (ICD-9-CM
codes 346.00, 346.01, 346.10, 346.11, 346.91, and 346.90);
however, we excluded other forms and variants of migraine, as
these diagnostic categories include conditions such as complicated and basilar migraine in which a triptan or DHE might be
contraindicated. The diagnosis of migraine was coded by the
treating physician. We analyzed race/ethnicity in 4 mutually exclusive categories: non-Hispanic white, non-Hispanic black,
Hispanic of any race, and all others.
The NHAMCS and NAMCS databases contain medication
codes for drugs administered or prescribed at each visit. We considered patients to have received standard abortive therapy if
they were given or prescribed any of the abortive medications
listed in table 1. In a sensitivity analysis, we included the 2 drugs
most commonly associated with visits for migraine, butalbital/
aspirin/caffeine and acetaminophen/dichloralphenazone/
isometheptene, in our list of abortive medications.14
For this study, we analyzed prophylactic medications recommended in the AAN⬘s latest practice guidelines on migraine,12
although we excluded NSAIDs because they are prescribed for
many more nonmigraine indications than other prophylactic
agents and are often given in EDs as an abortive treatment for
migraine, confounding our assessment of their use for prophylaxis. We considered patients to have received prophylactic therapy if they were given or prescribed any of the prophylactic
medications listed in table 1 or a medication with the generic
code for “beta blocker.”
Standard protocol approvals, registrations, and patient
consents. We obtained institutional review board approval for
this study.

Statistical analysis. We performed a multivariate analysis on
data from all visits associated with a diagnostic code for migraine, controlling for age, gender, race/ethnicity, region, urban
vs rural location, and year of visit in order to analyze the effect of
insurance status on the likelihood of receiving abortive and prophylactic migraine therapy. We then assessed the model for interaction between site of care and insurance, to see if
stratification by site of care was indicated. Because the interaction term was nonsignificant, we proceeded to analyze the effect
of site of care by adding this variable to the multivariate model.
We also tested whether later year of visit predicted receipt of
abortive or prophylactic therapy. All analyses account for the
complex survey design. We used weights provided by the NCHS
to yield national estimates. We performed these analyses using
SAS version 9.0 (Cary, NC).
RESULTS A total of 6,814 ambulatory visits for migraine were made to EDs, OPDs, and physicians’
offices over the 11-year study period, representing
68.6 million (95% confidence interval [CI] 62.4 milNeurology 74
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Table 1

Abortive and prophylactic medications
for migraine

Abortive medications

Prophylactic medications

Sumatriptan

Propranolol

Zolmitriptan

Metoprolol

Naratriptan

Atenolol

Rizatriptan

Nadolol

Frovatriptan

Timolol

Eletriptan

Verapamil

DHE 45 dihydroergotamine

Nimodipine
Valproate divalproex sodium
Topiramate
Gabapentin
Amitriptyline
Nortriptyline
Protriptyline
Desipramine
Doxepin
Imipramine
Trazodone
Venlafaxine
Bupropion
Paroxetine
Fluoxetine
Mirtazapine
Fluvoxamine
Sertraline
Phenelzine
Riboflavin vitamin B2
Feverfew
Migrelief
Cyproheptadine
Methysergide

lion, 74.7 million) visits to nonfederal facilities for
migraine nationwide. We display the patient and
provider characteristics of these visits, stratified by
visit location, in table 2. The uninsured accounted
for 7.9% of total migraine visits; however, they accounted for 6.3% of visits to office-based settings
and 15.7% of ED visits. This is in contrast to the
privately insured, who accounted for 60.2% of total
migraine visits, but 70% of office-based visits and
only 46.1% of ED visits. Although 17.2% of migraine visits were to the ED overall, only 13.2% of all
migraine care for the privately insured occurred in
EDs, compared to 34.1% of migraine care for the
uninsured. In the office setting, patients seen by primary care physicians were no more likely to be uninsured than those seen by neurologists (7.0% vs 3.5%,
2 p ⫽ 0.13).
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Table 3 shows the results of our multivariate analysis of data from all visits associated with a diagnostic
code for migraine, controlling for insurance status,
age, gender, race, region, urban vs rural location, and
year of visit. In these models, both lack of insurance
and Medicaid were associated with failure to receive
standard migraine treatment. The uninsured and
those with Medicaid were less likely than the privately insured to receive abortive treatment with a
triptan or DHE (OR for failure to receive either
medication 2.0 [95% CI 1.3, 3.0] and 1.6 [95% CI
1.1, 2.3]). The uninsured and those with Medicaid
were also less likely than those with private insurance
to receive prophylactic therapy (OR for failure to receive medication 2.0 [95% CI 1.3, 2.9] and 1.5
[95% CI 1.0, 2.1]).
Including site of care in the model reduced the
association between insurance status and likelihood
of receiving standard abortive and prophylactic medication, suggesting that the nationwide disparities in
migraine care are driven, at least in part, by inadequate access to office-based care for uninsured and
Medicaid patients. Those seen in the ED were much
less likely than those seen in non-ED ambulatory settings to receive standard abortive treatment and standard prophylactic treatment (OR for failure to
receive medication 4.8 [95% CI 3.6, 6.3] and 8.7
[95% CI 6.4, 11.7]). Nonetheless, for the uninsured, the trend toward substandard treatment remained substantial for both abortive therapy (OR
1.6 [95% CI 1.0, 2.5]) and prophylaxis (OR 1.5
[95% CI 1.0, 2.3]).
Age greater than 65 years was also associated with
failure to receive these abortive therapies, perhaps because contraindications to triptans are common in
the elderly, while Hispanics and those in the Midwest were less likely to receive prophylactic therapy.
Addition of butalbital/aspirin/caffeine and acetaminophen/dichloralphenazone/isometheptene to the list
of abortive medications did not change the relationship between uninsurance or Medicaid and the likelihood of failing to receive abortive treatment (OR
for failure to receive medication 2.0 [95% CI 1.3,
2.9] and 1.4 [95% CI 1.0, 2.2]).
In this study, we demonstrate that
among those who seek care for migraine, the uninsured are less likely than the privately insured to receive standard migraine therapy, when standard
therapy is defined as receiving a triptan or DHE and
receiving a prophylactic medication. Our results are
based on a nationally representative sample and are
generalizable to the entire United States. Approximately 15% of the United States population, 45.7
million individuals, is currently uninsured.15 Given a

DISCUSSION

Table 2

Patient and provider characteristics of migraine headache visits to
United States physician offices, hospital outpatient departments,
and emergency departments, 1997–2007
Office-based settings
Physician
offices
(n ⴝ 2,244)

Hospital outpatient
departments
(n ⴝ 1,447)

Emergency
departments
(n ⴝ 3,123)

53.1 million

3.7 million

11.8 million

18–40 years

42.6

53.7

61.1

41–65 years

51.1

43.2

36.7

>65 years

6.3

3.2

2.2

Non-Hispanic white

79.8

70.7

78.7

Non-Hispanic black

8.1

15.5

13.1

Hispanic, any race

8.3

10.3

6.3

Other

3.7

3.5

2.0

83.6

85.4

82.9

Private insurance

71.5

48.7

46.1

Uninsured

6.2

7.9

15.7

Medicaid

8.4

25.5

21.6

Medicare

8.0

7.3

8.4

Worker’s compensation

0.1

0.1

0.3

Unknown payer

5.8

10.5

7.9

Northeast

16.5

24.6

13.3

Midwest

25.2

31.7

26.3

South

34.8

27.9

39.7

West

23.4

15.8

20.7

81.5

77.8

71.2

Voluntary nonprofit

76.0

71.4

Government, nonfederal

21.0

16.2

Proprietary

3.0

12.3

Total weighted visits nationally
Age, weighted %

Race/ethnicity, %

Gender, %
Female
Anticipated source of payment, %

Region, %

Urban/rural location, %
MSA
Hospital owner, %

Provider type
Neurologist

19.6

Primary care physician

67.9

Other

12.6

Abbreviation: MSA ⫽ medical provider located in a Metropolitan Statistical Area, as defined
by the Office of Management and Budget.

12% prevalence of migraine, we estimate that 5.5
million Americans risk substandard treatment of
their migraine and consequent avoidable suffering
and disability. We also found that patients insured
by Medicaid were less likely than the privately insured to be prescribed abortive or prophylactic medication, although the effect was smaller than that seen
for the uninsured, a reminder that access to some

forms of insurance is not the same as access to adequate care.
In exploring mechanisms for these disparities, we
found that site of care was critical, although the odds
of substandard treatment for uninsured migraineurs
remained somewhat elevated for both abortive and
prophylactic therapy, suggesting that site of care is
not the only explanation for the disparity in treatment. The uninsured are more likely than the privately insured to receive substandard treatment in
large part because they are more likely to receive care
for migraine in EDs rather than physician offices.
Unfortunately, 20% of the uninsured (vs 3% of
those with coverage) say their usual source of care is
the ED; the uninsured are also much less likely than
the insured to have a regular source of medical care.16
While we cannot exclude the possibility that the uninsured have more severe headaches than the insured,
we presume that they receive migraine care in the ED
as a last resort. Our data add to prior evidence that
migraine care in EDs is suboptimal. In a study of 219
patients presenting to an ED for headache, 47.5% of
whom were diagnosed with migraine by a neurologist’s chart review, only 40.6% were asked to follow
up with a physician and only 37.4% had any documented discharge medications.17
The high cost of some migraine medications is
another possible mechanism for some of the disparities we document. Injectable sumatriptan ($19/dose
in 2009 prices) became available in the United States
in 1991 and oral sumatriptan ($26/100 mg tablet) in
1995; no generic triptans were available during the
years of our study. However, adding the less expensive butalbital/aspirin/caffeine ($1/tablet) and
acetaminophen/dichloralphenazone/isometheptene
($0.73/tablet) to our list of abortive medications did
not change the relationship of uninsurance and Medicaid coverage to substandard treatment, suggesting
that the availability of moderately priced medications
is not sufficient to reduce disparities in migraine care
for those without private insurance.
The substandard treatment of migraine in the uninsured and Medicaid populations has significant financial implications. A study of the effect of
initiating sumatriptan treatment in migraine patients
found that over a 6-month follow-up period,
sumatriptan reduced the total migraine disability
time from 27.8 to 17.2 days per person. Quantifying
the economic impact of this disability time based on
national average wage rates, and taking into account
migraine-related medical costs, this study estimated
that sumatriptan use generated a net cost savings of
$2,498 per patient per year.18
Prior studies have documented that migraine care
is often suboptimal in the United States; for example,
Neurology 74
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Table 3

Multivariate odds that US adults will fail to receive standard migraine
treatment, all ambulatory sites of care: National Ambulatory
Medical Care Survey and National Hospital Ambulatory Medical
Care Survey, 1997–2007
Abortive medication,
odds ratio (95% CI)

Prophylactic medication,
odds ratio (95% CI)

Privately insured (ref)

1.0

1.0

Uninsured

2.0a (1.3, 3.0)

2.0a (1.3, 2.9)

Medicaid

1.6a (1.1, 2.3)

1.5a (1.0, 2.1)

1.6 (0.9, 2.7)

1.4 (0.9, 2.4)

Characteristic
Insurance status

Medicare
Worker’s compensation

b

a

3.4 (1.0, 11.5)

3.0 (0.4, 23.2)

1.4 (0.8, 2.3)

1.8a (1.2, 2.7)

Female (ref)

1.0

1.0

Male

0.8 (0.6, 1.1)

1.1 (0.9, 1.5)

Other
Gender

Age
18–40 y (ref)

1.0

1.0

41–65 y

1.0 (0.8, 1.3)

0.8 (0.7, 1.1)

>65 y

3.8a (1.7, 8.5)

0.8 (0.4, 1.4)

Race
Non-Hispanic white (ref)

1.0

1.0

Hispanic

1.1 (0.7, 1.6)

2.1a (1.3, 3.2)

Non-Hispanic black

1.1 (0.7, 1.8)

1.1 (0.7, 1.7)

Otherb

2.4a (1.1, 5.1)

2.1a (1.1, 3.9)

Northeast (ref)

1.0

1.0

Midwest

0.8 (0.6, 1.2)

1.5a (1.0, 2.2)

South

1.1 (0.8, 1.5)

1.3 (0.9, 1.9)

West

1.1 (0.7, 1.7)

1.2 (0.8, 1.7)

Region

Urban/rural location
Rural (ref)

1.0

1.0

Metropolitan area

0.8 (0.6, 1.1)

0.7 (0.5, 1.1)

1.0a (1.0, 1.1)

1.1a (1.0, 1.1)

Year of visitc

Abbreviations: CI ⫽ confidence interval; ref ⫽ reference group.
a
Statistically significant result.
b
Results based on small numbers of visits.
c
Odds ratio equals the change for each successive year of visit.

while 25.7% of migraineurs met criteria for prophylaxis, only 13% were actually receiving it.1 Only 29%
of migraineurs are very satisfied with their usual
acute treatment.19 Our finding that Hispanics receive
less prophylactic medication, regardless of insurance
status, suggests that language barriers may also deter
optimal migraine care. However, our data strongly
suggest that absent or inadequate insurance is a major contributor to substandard care for migraine.
In the United States, migraine prevalence is inversely related to household income.1,2 Migraines
may lead to lower socioeconomic status by impairing
school and work performance. Some data suggest
that the converse explanation is more likely; namely,
1182
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that low income increases the risk of migraine.20 Our
findings suggest that inadequate insurance magnifies
the already high burden of migraine on low-income
families.
Our study has limitations. The treating clinician
made the diagnosis of migraine; we had no independent verification of diagnosis. While the misdiagnosis of migraine is important clinically, it would not
invalidate our study findings because we are studying
the effect of insurance status on prescribing behavior
at visits where the prescriber diagnoses migraine. We
were also unable to assess migraine severity. However, given that most migraine is moderate to severe,
with 91% of migraineurs reporting functional impairment, our assumption that rates of moderate to
severe migraine are similar among groups seems reasonable.2 We also had no data on the duration of
individual migraines; some patients seen in the ED
may have had intractable headaches for which
triptans are less effective and thus less likely to be
prescribed.
Another limitation of our study is that our definition of prophylactic medication was, by necessity,
broad; some of the individuals receiving these medications may have done so for indications other than
migraine. It is also possible that some individuals
were receiving standard migraine therapy, but that it
was not administered or prescribed during the sampled visit. However, there is no a priori reason to
expect that either of these issues would preferentially
affect one group more than another.
Using the prescription of a triptan or DHE or the
prescription of a prophylactic agent as proxies for
standard care of migraine headache, we have found
that the uninsured are twice as likely as the privately
insured to receive substandard migraine care. Migraineurs insured by Medicaid are also more likely to
receive substandard care. This effect appears to be
mediated in large part by the fact that the uninsured
and Medicaid-insured receive more of their migraine
care in the ED. Given the economic and humanitarian costs of undertreated migraine, neurologists
should advocate for comprehensive coverage of physician care and standard medications to minimize
migraine’s toll.
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